Serum aspartate aminotransferase, a novel potential biomarker of prognosis in extranodal natural killer/T cell lymphoma, nasal type.

IF 2.2 4区医学 Q3 ONCOLOGY

Cancer Biomarkers Pub Date : 2024-01-01 DOI:10.3233/CBM-230068

Ningning Yao, Qing Hou, Yu Liang, Xin Cao, Bochen Sun, Lijuan Wei, Ruifang Sun, Jianzhong Cao

{"title":"Serum aspartate aminotransferase, a novel potential biomarker of prognosis in extranodal natural killer/T cell lymphoma, nasal type.","authors":"Ningning Yao, Qing Hou, Yu Liang, Xin Cao, Bochen Sun, Lijuan Wei, Ruifang Sun, Jianzhong Cao","doi":"10.3233/CBM-230068","DOIUrl":null,"url":null,"abstract":"Background: Aspartate aminotransferase (AST), an indicator of liver cell damage, was related to the prognosis of certain malignant tumors.Objective: This study examined the predictive value of AST in patients with extranodal natural killer/T cell lymphoma (ENKTL).Methods: We reviewed 183 cases diagnosed with ENKTL and selected 26 U/L as the optimum cut-off value of AST. We used the univariate and multivariate Cox regression to compare the different AST groups' overall survival (OS) and progression-free survival (PFS).Results: Prior to propensity score matching (PSM), Kaplan-Meier analysis showed that patients in the low AST subgroup had better OS and PFS than the high AST subgroup. Multivariate analysis revealed that AST was an independent indicator for prognosis. After PSM, the low AST subgroup maintained a significantly better OS and PFS than the high AST subgroup.Conclusion: AST might represent a significant prognostic marker for ENKTL patients.","PeriodicalId":56320,"journal":{"name":"Cancer Biomarkers","volume":" ","pages":"265-275"},"PeriodicalIF":2.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11191476/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3233/CBM-230068","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Aspartate aminotransferase (AST), an indicator of liver cell damage, was related to the prognosis of certain malignant tumors.

Objective: This study examined the predictive value of AST in patients with extranodal natural killer/T cell lymphoma (ENKTL).

Methods: We reviewed 183 cases diagnosed with ENKTL and selected 26 U/L as the optimum cut-off value of AST. We used the univariate and multivariate Cox regression to compare the different AST groups' overall survival (OS) and progression-free survival (PFS).

Results: Prior to propensity score matching (PSM), Kaplan-Meier analysis showed that patients in the low AST subgroup had better OS and PFS than the high AST subgroup. Multivariate analysis revealed that AST was an independent indicator for prognosis. After PSM, the low AST subgroup maintained a significantly better OS and PFS than the high AST subgroup.

Conclusion: AST might represent a significant prognostic marker for ENKTL patients.

查看原文本刊更多论文

血清天冬氨酸氨基转移酶--鼻型结节外自然杀伤/T细胞淋巴瘤预后的潜在新型生物标志物

背景：作为肝细胞损伤指标的天冬氨酸氨基转移酶（AST）与某些恶性肿瘤的预后有关：天冬氨酸氨基转移酶（AST）是肝细胞损伤的指标，与某些恶性肿瘤的预后有关：本研究探讨了天冬氨酸氨基转移酶在结外自然杀伤/T细胞淋巴瘤（ENKTL）患者中的预测价值：方法：我们回顾了183例确诊为ENKTL的病例，并选择26 U/L作为AST的最佳临界值。我们采用单变量和多变量 Cox 回归比较了不同 AST 组的总生存期（OS）和无进展生存期（PFS）：结果：在倾向评分匹配（PSM）之前，卡普兰-梅耶分析显示，低AST亚组患者的OS和PFS均优于高AST亚组。多变量分析显示，AST是预后的独立指标。PSM 后，低 AST 亚组的 OS 和 PFS 明显优于高 AST 亚组：结论：AST可能是ENKTL患者的一个重要预后指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Biomarkers ONCOLOGY-

CiteScore

5.20

自引率

3.20%

发文量

195

审稿时长

3 months

期刊介绍： Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings (and reviews solicited by the editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion. The disease markers may include, but are not limited to, genomic, epigenomic, proteomics, cellular and morphologic, and genetic factors predisposing to the disease or indicating the occurrence of the disease. Manuscripts on these factors or biomarkers, either in altered forms, abnormal concentrations or with abnormal tissue distribution leading to disease causation will be accepted.